Article

Successful factor XIII administration for persistent chylothorax after lung transplantation for lymphangioleiomyomatosis.

Department of General Thoracic Surgery, Osaka University Graduate, School of Medicine, Osaka, Japan.
The Annals of thoracic surgery (impact factor: 3.74). 10/2009; 88(3):1003-6. DOI:10.1016/j.athoracsur.2009.01.048 pp.1003-6
Source: PubMed

ABSTRACT Lung transplantation has emerged as a viable treatment option for patients with end-stage lymphangioleiomyomatosis (LAM), and therapeutic outcome results reported thus far have been satisfactory. However, persisting chylothorax after transplantation for LAM remains a challenging problem, and the optimal management has not been decided. We present the case with persistent chylothorax after lung transplantation for LAM, in which the intravenous administration of a tissue repair factor (human factor XIII) resulted in complete resolution of chylous effusion without performing additional invasive treatments, leading to a successful transplant outcome.

0 0
 · 
0 Bookmarks
 · 
39 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

challenging problem
 
human factor XIII
 
intravenous administration
 
LAM
 
lung transplantation
 
patients
 
persistent chylothorax
 
persisting chylothorax
 
successful transplant outcome
 
therapeutic outcome results
 
transplantation
 
viable treatment option